Holen Sie sich die Stockscreener-App
316.64
1.47%
4.59
Handel nachbörslich:
316.64
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CI?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$312.05
Offen:
$312.28
24-Stunden-Volumen:
2.73M
Relative Volume:
1.57
Marktkapitalisierung:
$84.59B
Einnahmen:
$254.47B
Nettoeinkommen (Verlust:
$5.03B
KGV:
17.53
EPS:
18.06
Netto-Cashflow:
$6.01B
1W Leistung:
+0.21%
1M Leistung:
-6.10%
6M Leistung:
-6.26%
1J Leistung:
-4.34%
1-Tages-Spanne:
$310.05
$319.25
1-Wochen-Bereich:
$308.39
$319.25
52-Wochen-Spanne:
$262.03
$370.82
Cigna Group Stock (CI) Company Profile
Firmenname
Cigna Group
Sektor
Branche
Telefon
(860) 226-6000
Adresse
900 COTTAGE GROVE ROAD, BLOOMFIELD, CT
Vergleichen Sie CI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CI
Cigna Group
|
316.64 | 84.41B | 254.47B | 5.03B | 6.01B | 18.06 |
|
UNH
Unitedhealth Group Inc
|
301.91 | 268.12B | 410.06B | 22.11B | 24.86B | 23.88 |
|
ELV
Elevance Health Inc
|
383.84 | 84.11B | 183.12B | 5.92B | 3.67B | 25.63 |
|
CVS
Cvs Health Corp
|
64.04 | 76.95B | 378.96B | 5.28B | 5.94B | 4.19 |
|
HUM
Humana Inc
|
233.13 | 27.15B | 117.76B | 1.21B | 2.39B | 9.95 |
Cigna Group Stock (CI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-06 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-06-26 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-06 | Eingeleitet | Barclays | Overweight |
| 2024-02-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-02-05 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-01 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-01-04 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2023-12-11 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-18 | Herabstufung | Edward Jones | Buy → Hold |
| 2023-06-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-04-21 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2023-04-05 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-11-23 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-11-21 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2022-07-14 | Herabstufung | Jefferies | Buy → Hold |
| 2022-06-22 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-17 | Eingeleitet | Loop Capital | Hold |
| 2022-05-27 | Fortgesetzt | Bernstein | Mkt Perform |
| 2022-05-26 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-05-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-05-09 | Hochstufung | Cowen | Market Perform → Outperform |
| 2022-02-07 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-02-04 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-01-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-12-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-14 | Eingeleitet | Goldman | Neutral |
| 2021-11-17 | Eingeleitet | Seaport Research Partners | Buy |
| 2021-09-27 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-09-10 | Eingeleitet | Cowen | Market Perform |
| 2021-08-06 | Bestätigt | BofA Securities | Buy |
| 2021-08-06 | Bestätigt | Citigroup | Buy |
| 2021-08-06 | Bestätigt | Deutsche Bank | Buy |
| 2021-08-06 | Bestätigt | Jefferies | Buy |
| 2021-08-06 | Bestätigt | Mizuho | Buy |
| 2021-08-06 | Bestätigt | Oppenheimer | Outperform |
| 2021-08-06 | Bestätigt | Truist | Buy |
| 2021-05-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-07-01 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-05-04 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-03-24 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-12-11 | Herabstufung | Wells Fargo | Market Perform → Underperform |
| 2019-10-18 | Eingeleitet | Mizuho | Buy |
| 2019-09-30 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Buy |
| 2019-08-06 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2019-04-23 | Eingeleitet | UBS | Buy |
| 2019-01-14 | Eingeleitet | Stephens | Overweight |
| 2018-12-24 | Eingeleitet | Edward Jones | Buy |
| 2018-03-13 | Eingeleitet | Bernstein | Mkt Perform |
| 2018-03-08 | Eingeleitet | Barclays | Overweight |
| 2018-01-03 | Eingeleitet | Goldman | Neutral |
| 2017-11-03 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-06-22 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-06-12 | Eingeleitet | Credit Suisse | Outperform |
| 2017-06-07 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-05-08 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-04-05 | Eingeleitet | Deutsche Bank | Buy |
Alle ansehen
Cigna Group Aktie (CI) Neueste Nachrichten
Here's How Much $100 Invested In Cigna Group 15 Years Ago Would Be Worth TodayCigna Group (NYSE:CI) - Benzinga
The Cigna Group Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
Cigna, CVS sue to block Arkansas' PBM regulation - HealthExec
Ex-Dividend Reminder: The Cigna Group, Macerich and Live Oak Bancshares - Nasdaq
CVS Health, Cigna sue Arkansas over PBM law (CVS:NYSE) - Seeking Alpha
The Cigna Group (CI): A Bull Case Theory - Insider Monkey
Express Scripts sues to block Arkansas law barring PBM ownership of pharmacies - marketscreener.com
Cigna Health Insurance Review 2025 - Forbes
Express Scripts sues Arkansas over new PBM law - Talk Business & Politics
Cigna study: High health insurance literacy associated with improved vitality, work productivity, and health outcomes - The Business Journals
The Cigna Group (NYSE:CI) Passed Our Checks, And It's About To Pay A US$1.51 Dividend - simplywall.st
Why You Might Be Interested In The Cigna Group (NYSE:CI) For Its Upcoming Dividend - Yahoo Finance
Personalized support for complex health care needs - Cigna Healthcare Newsroom
2 Reasons to Like CI and 1 to Stay Skeptical - FinancialContent
CVS or Cigna: Which Diversified Healthcare Stock Should You Own Now? - TradingView
The Zacks Analyst Blog Highlights Costco Wholesale, Chubb, Cigna, Global Self Storage and Natural Health Trends - Yahoo Finance
Cigna’s SWOT analysis: stock poised for growth amid healthcare challenges - Investing.com
UBS Maintains Buy Rating on Cigna (CI) Stock - MSN
Molson Coors and Cigna Head My “Do Nothing” Stock List - TribLIVE.com
UBS maintains Cigna stock Buy rating with $390 target - Investing.com
Top Research Reports for Costco, Chubb & Cigna - Yahoo Finance
Guggenheim Reiterates Buy Rating for Cigna Group (CI) with $388 Price Target | CI Stock News - GuruFocus
Cigna Adds Kerecis Intact Fish-Skin Grafts to Coverage Policy - Business Wire
Cigna's (CI) Evernorth Secures Open Access for Key Products | CI Stock News - GuruFocus
Cigna Announced a New Agreement for Copay Caps on Eli Lilly and Novo Nordisk Weight Loss Drugs - MSN
FTC Scraps PepsiCo Price Discrimination Case In 3-0 Vote, Marking Major Shift As Trump-Era Leadership Reverses Biden CrackdownCVS Health (NYSE:CVS), Cigna Group (NYSE:CI) - Benzinga
Cigna is putting a cap on weight loss drug costs - Yahoo Finance
Cigna (CI) Caps Out-of-Pocket Costs on Weight-Loss Drugs for Pat - GuruFocus
Cigna (CI) Caps Out-of-Pocket Costs on Weight-Loss Drugs for Patients | CI Stock News - GuruFocus
Cigna (CI) Expands Access to Weight Loss Medications with New Ph - GuruFocus
Cigna (CI) Unit Launches Cost-Effective Pharmacy Benefit for Wei - GuruFocus
Cigna (CI) Launches Cost-Effective Benefit Option for Weight Loss Drugs | CI Stock News - GuruFocus
Cigna (CI) Caps Weight-Loss Drug Costs, Impact on Telehealth Offerings | CI Stock News - GuruFocus
Former employees sue Cigna's 401(k) fiduciaries for misusing forfeited employer match money - Pensions & Investments
Pharmalittle: We're reading about rising drug prices, Cigna's plan for weight loss drugs, and more - statnews.com
Cigna to offer $200 Wegovy, Zepbound weight-loss benefit - Reuters
Cigna (CI) Launches Cost-Capping Program for Weight-Loss Drugs - GuruFocus
Cigna’s Evernorth caps weight-loss drug copays at $200/month (CI:NYSE) - Seeking Alpha
Cigna Offers New Weight-Loss Drug Pricing Plan to Boost Use - Bloomberg
Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs - MSN
Cigna (CI) Faces Increased Scrutiny Amid Expanded Medicare Audits | CI Stock News - GuruFocus
Cigna Group's Evernorth Launches Benefit Option to Lower Weight Loss Medicine Costs - marketscreener.com
Cigna (CI) Affected by Medicare Advantage Audit Expansion | CI Stock News - GuruFocus
Evernorth Launches New Benefit Option That Drives Lower Net Cost for Weight Loss Medicines and Limits Patient Cost to No More Than $200 Per Month - Quantisnow
Cigna Accused of Misusing Retirement Plan Funds - USA Herald
Baird Adjusts Price Target on Cigna Group to $364 From $362, Maintains Outperform Rating - marketscreener.com
Cigna Accused Of Mismanaging Retirement Plan Funds - Law360
2nd Circ. Affirms Dismissal Of Lab's Payment Suit Against Cigna - Law360
Here's How Much You Would Have Made Owning Cigna Group Stock In The Last 20 Years - Benzinga
Cigna Group (CI) Reaffirms 2025 Financial Outlook - GuruFocus
Cigna Reaffirms 2025 Earnings Projection Amid Investor Meetings - TipRanks
Finanzdaten der Cigna Group-Aktie (CI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):